Literature DB >> 17185518

SFK-STAT pathway: an alternative and important way to malignancies.

Fumihiko Hayakawa1, Tomoki Naoe.   

Abstract

Signal transducers and activators of transcription (STAT) proteins play a crucial role in mediating signals from a diverse spectrum of cytokine receptors. STAT is thought to be activated by JAK family kinases (JFK) in many cytokine receptor signal pathways; however, recent studies have demonstrated an alternative pathway to activate STAT by Src family kinases (SFK) in growth factor receptor signal. We also observed STAT5 phosphorylation by Lyn, a member of SFK, in our two recent studies. We introduce these studies and review the literature of STAT activation by SFK and aberrant activation of STAT by oncogenic signals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185518     DOI: 10.1196/annals.1377.002

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  8 in total

1.  Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors.

Authors:  M Kondyli; G Gatzounis; A Kyritsis; J Varakis; M Assimakopoulou
Journal:  J Neurooncol       Date:  2010-03-25       Impact factor: 4.130

Review 2.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

Review 3.  The diverse functions of Src family kinases in macrophages.

Authors:  Clare L Abram; Clifford A Lowell
Journal:  Front Biosci       Date:  2008-05-01

4.  Toxoplasma rhoptry protein 16 (ROP16) subverts host function by direct tyrosine phosphorylation of STAT6.

Authors:  Yi-Ching Ong; Michael L Reese; John C Boothroyd
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

Review 5.  Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling cross talk.

Authors:  Clifford A Lowell
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

6.  Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer.

Authors:  Ning Su; Liang Peng; Bingqing Xia; Yingying Zhao; Angao Xu; Jing Wang; Xinying Wang; Bo Jiang
Journal:  Mol Cancer       Date:  2012-06-26       Impact factor: 27.401

7.  Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.

Authors:  Michinori Ogura; Toshiki Uchida; Yasuhito Terui; Fumihiko Hayakawa; Yukio Kobayashi; Masafumi Taniwaki; Yasushi Takamatsu; Tomoki Naoe; Kensei Tobinai; Wataru Munakata; Takeshi Yamauchi; Akiko Kageyama; Miyuki Yuasa; Masaaki Motoyama; Takeshi Tsunoda; Kiyohiko Hatake
Journal:  Cancer Sci       Date:  2015-05-25       Impact factor: 6.716

8.  A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.

Authors:  F Hayakawa; K Sugimoto; Y Harada; N Hashimoto; N Ohi; S Kurahashi; T Naoe
Journal:  Blood Cancer J       Date:  2013-11-29       Impact factor: 11.037

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.